Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma

Cancer

Volumn 78, Issue 11, 1996, Pages 2346-2352

  Yamashita, Jun Ichi ^a   Hideshima, Teru ^b   Shirakusa, Takayuki ^b   Ogawa, Michio ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

breast carcinoma; medroxyprogesterone acetate; serum interleukin 6

Indexed keywords

FLUOROURACIL; INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN;

ADULT; AGED; APPETITE; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT GAIN; WELLBEING;

ADMINISTRATION, ORAL; ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-6; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NEOPLASM PROTEINS; PROGESTERONE CONGENERS; PROSPECTIVE STUDIES;

EID: 0029843366     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961201)78:11<2346::AID-CNCR12>3.0.CO;2-0     Document Type: Article

References (38)

1. Pannuti F, Di Marco AR, Martoni A, Fruet F, Strocchi E, Burroni P, et al. Medroxyprogesterone acetate in the treatment of metastatic breast cancer: seven years of experience. In: Iacobelli S, Di Marco A. Role of medroxyprogesterone in endocrine-related tumors: progress in cancer research and therapy. Volume 15. New York: Raven Press, 1980: 73-92.
2. Robustelli Della Cuna G, Bernardo-Strada MR, Ganzina F. High dose medroxyprogesterone acetate in metastatic breast cancer: a critical review. In: Cavalli F, McGuire WL, Pannuti F, Pellegrini A, Robustelli Della Cuna G. Proceedings of the International Symposium on Medroxyprogesterone Acetate. Amsterdam, Oxford, Princeton: Excerpta Medica, 1982: 290-305.
3. Johnson JR, Priestman TJ, Fotherby K, Kelly KA, Priestman SG. An evaluation of high-dose medroxyprogesterone acetate therapy in women with advanced breast cancer. Br J Cancer 1984;50:363-6.
4. Hsueh AJW, Peck JEJ, Clark JH. Progesterone antagonism of the oestrogen receptor and oestrogen-induced uterine growth. Nature 1975;254:337-9.
5. Carlo FD, Conti G, Reboani C. Interference of gestagens and androgens with rat uterine oestrogen receptors. J Endocrinol 1978;77:49-55.
6. Hellman L, Yoshida K, Zumoff B, Levin J, Kream J, Fukushima DK. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab 1976; 42:912-7.
7. Danguy A, Legros N, Devleeschouwer N, Heuson-Stennon JA, Heuson JC. Effects of medroxyprogesterone acetate (MPA) on growth of DMBA-induced rat mammary tumors: histopathologic and endocrine studies. In: Iacobelli S, Di Marco A. Role of medroxyprogesterone in endocrine-related tumors: progress in cancer research and therapy. Volume 15. New York: Raven Press, 1980:21-8.
8. Blossey HC, Wander HE, Koebberling J, Nagel GA. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer 1984;54:1208-15.
9. Hirano T, Yasaukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, et al. Complementary DNA for a novel interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986;324:73-9.
10. Kishimoto T. The biology of interleukin 6. Blood 1990;74:1-10.
11. Hirano T. Interleukin-6. In: Thomson A. The cytokine handbook. London: Academic Press Ltd, 1991:169-90.
12. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 1993;53:2118-22.
13. Blay J, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of interleukin 6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992;52:3317-22.
14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
15. Tamassia V, Preti P, Moro E. MPA pharmacokinetics: blood levels and therapeutic efficacy. In: Nagel GA. German-Italian Oncological Symposium: MPA in the therapy of hormone dependent tumors. 1984:11-20.
16. Milano G, Carle G, Renee N. Determination of medroxyprogesterone acetate in plasma by high performance liquid chromatography. J Chromatogr Sci 1982;232:413-7.
17. Van Meir EV, Sawamura Y, Diserens A-C, Hamou M-F, de Tribolet N. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res 1990;50:6683-8.
18. Tabibzadeh SS, Poubouridis D, May LT, Sehgal PB. Interleukin-6 immunoreactivity in human tumors. Am J Pathol 1989;135:427-33.
19. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 1990;50:6959-65.
20. Siegall CB, Schwab G, Nordan RP. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 1990;50:7784-8.
21. Ishiko T, Mita S, Sakamoto K, Ogawa M, Fibroblast-tumor interaction changes constitutive expression of IL-6 and IL-8 in human carcinoma cells. Int J Oncol 1995;6:639-45.
22. Adams EF, Rafferty B, White MC. Interleukin 6 is secreted by breast fibroblasts and stimulates 17β-oestradiol oxidoreductase activity of MCF-7 cells: possible paracrine regulation of breast 17β-oestradiol levels. Int J Cancer 1991; 49:118-21.
23. Yamashita J, Hideshima T, Shirakusa T, Ogawa M. Primary tumor levels of interleukin 6 in relation to tumor burden in human breast cancer. Oncology Reports 1994;1:1185-7.
24. Etienne MC, Milano G, Frenay M, Renee N, Francois E, Thyss A, et al. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients. J Clin Oncol 1992;10:1176-82.
25. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266-300.
26. Basedovsky H, Del Rey A. Immune-neuroendocrine circuits: integrative role of cytokines. Front Neuroendocrinol 1992; 13:61-94.
27. Bateman A, Singh A, Kral T, Solomon S. The immune-hypothalamic-pituitary-adrenal axis. Endocr Rev 1989;10:92-112.
28. Hermus ARMM, Sweep CGJ. Cytokines and the hypothalamic-pituitary-adrenal axis. J Steroid Biochem Mol Biol 1990;37:867-71.
29. Spangelo BL, Judo AM, Isakson PC, MacLeod RM. Interleukin-6 stimulates anterior pituitary hormone release in vitro. Endocrinology 1989;125:575-7.
30. Arzt E, Buric R, Stelzer G, Stalla J, Sauer J, Renner U, et al. Interleukin involvement in anterior pituitary cell growth regulation: effects of IL-2 and IL-6. Endocrinology 1993; 132:459-67.
31. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84:2008-11.
32. Tamm I, Cardinale I, Krueger J, Murphy JS, May LT, Sehgal PB. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J Exp Med 1989;170:1649-69.
33. Tamm I, Cardinale I, Murphy JS. Decreased adherence of interleukin 6-treated breast carcinoma cells can lead to separation from neighbors after mitosis. Proc Natl Acad Sci U S A 1991;88:4414-8.
34. Yamashita J, Ogawa M, Nomura K, Matsuo S, Inada K, Yamashita S, et al. Interleukin 6 stimulates the production of immunoreactive endothelin 1 in human breast cancer cells. Cancer Res 1993;53:464-7.
35. Tchekmedyian NS, Tait N, Moody M, Greco FA, Ansner J. Appetite stimulation with megestrol acetate in cachectic cancer patients. Semin Oncol 1986;13:37-43.
36. Sedlacek SM. An overview of megestrol acetate for the treatment of advanced breast cancer. Semin Oncol 1988;15:3-13.
37. Ross MB, Buzdar AU, Blumenschein GR. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer 1982;49:413-7.
38. Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-32.